Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)

Summary

A single arm, open label, prospective, phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous gefitinib failure. Primary endpoint * to assess Disease Control Rate (Remission + Stable disease) Secondary endpoints * to assess the progression free survival

Timeline

Start

2009-01

Primary completion

2011-06

Completion

2011-12

Publications

• Results Oh IJ, Ban HJ, Kim KS, Kim YC. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer. 2012 Jul;77(1):121-7. doi: 10.1016/j.lungcan.2012.01.012. Epub 2012 Feb 12.

Drugs

Indications